Tourmaline Bio Inc. has announced amendments to its Executive Severance and Change in Control Plan as of September 8, 2025. Under the revised plan, in the event of a termination during the designated Change in Control Period, key executives, including Chief Financial Officer Ryan Robinson and Chief Business Officer Brad Middlekauff, will receive a lump sum payment comprising 15 months of their current annual base salary and 125% of their annual target bonus. Additionally, they will be entitled to up to 15 months of group health insurance continuation benefits. These changes aim to provide enhanced financial security to the executives during significant corporate transitions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tourmaline Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-202252), on September 12, 2025, and is solely responsible for the information contained therein.